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Background: Hand eczema has a one-year prevalence of approximately 10 % in the general Danish population.
Often the disease becomes chronic with numerous implications for the individual’s daily life, occupation and quality
of life. However, no guidelines of self-management recommendations beyond the acute stage are given. Self-
management of the disease is pivotal and involves self-monitoring of the condition, medication adherence, and
preventive behaviour. Interventions best to support the individual in this ongoing process need to be developed.
Methods/design: This paper describes the design of a randomised clinical trial to test a newly developed
intervention of individual counselling versus conventional information. 300 patients consecutively referred to
dermatologic treatment at two different settings are individually randomised to either the intervention programme,
named ‘The Healthy Skin Clinic’ or to the control group. Block-wise randomisation according to setting and gender
is carried out.
The intervention offers a tool for self-monitoring; basic and specific individual counselling; the possibility of
asynchronous communication with the intervention team; and an electronic patient dialogue forum. Primary
outcome variable is objective assessment of the hand eczema severity performed at baseline prior to
randomisation, and repeated at six months follow-up. Secondary outcome variables are dermatology related life
quality and perceived global burden of disease.
Discussion: The trial aims at evaluating a newly developed guidance programme which is expected to support
self-management of patients referred to dermatology treatment due to chronic hand eczema. The design of the
protocol is pragmatic with blinding of neither participants nor the investigator. Thus, in the interpretation of the
results, the investigator takes into account effects that may be attributed to actors of the interventions rather than
the intervention per se as well of potential observer bias. Inclusion criterions are wide in order to increase
transferability of the results.
Trial registration: The trial is registered in ClinicalTrials.Gov with registration number NCT01482663.
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Hand eczema is a pruritic inflammatory skin disease
characterised in the acute phase by erythema, oedema
and sometimes vesicles, while in the chronic state the
skin changes are dominated by infiltration, scaling and
fissures, which may cause pain. The disease is common
[1]; in a recent Danish study a one-year prevalence of
14% was found, of which 23% had severe or moderate
eczema [2]. Hand eczema is not a uniform disease as it
exists in a continuum of severity with variations in
morphology. Aetiologically, hand eczema may be due to
irritant contact dermatitis, which is most prevalent fol-
lowed by allergic contact dermatitis and atopic hand ec-
zema [3]. Multi-causality is frequent and in order to
provide adequate treatment and tertiary prevention
aetiological factors need to be determined [4].
Hand eczema often has a chronic course with symp-
toms persisting 10–15 years after onset [3,5] and with
psychosocial consequences such as long term sick leave,
involuntary job rotation or early retirement [5]. Further-
more, quality of life has been shown to correlate nega-
tively to the severity of the disease [4,6]. No consensual
definition of chronic hand eczema exists although some
authors have used the definition of hand eczema which
persists throughout more than three months or which
reoccurs twice or more within a 12 month time frame
[7]. Chronic hand eczema typically has a dynamic course
with intermittent eruptions of eczema [4]. A guideline
for the overall treatment principles for hand eczema has
been proposed by the Danish Contact Dermatitis Group
[4]. However, although chronic hand eczema affects nu-
merous functions in daily life, no specific recommenda-
tions as to self-manage the disease beyond the acute
stage are given. Patients’ knowledge of their diagnosis
may determine their prognosis [8]. Also, medical treat-
ment of hand eczema is often prolonged and should be
accompanied by skin protection and skin care measures
[9]. However, some evidence based recommendations of
skin protection may be experienced as complex [10].
Among dermatological patients it is estimated that
34–45% do not comply with instructions regarding med-
ical treatment [11,12]. This may also depend on the sat-
isfaction with and an overall experience of effectiveness
of the treatment [13]. The patient’s self-management in
the course is pivotal as it applies both to handling the
acute eczema and to the continuous preventive behav-
iour, necessary to avoid relapses of the disease. Yet, evi-
dence related to self-management of hand eczema is
poor. In chronic illness generally, interventions that aim
at increasing medication adherence, and thus indirectly
the patient’s self-management, are most effective when
intervening in several dimensions [14,15]. Better meth-
ods to support self-management of patients with chronic
hand eczema may potentially improve the prognosis of adisease that is both a burden to the individual and to so-
ciety. Hand eczema is often caused or aggravated by oc-
cupational exposures such as wet work, food handling,
cutting oils etc. In several studies, interventions aiming
at secondary prevention of occupational irritant hand ec-
zema have been examined [16]. Comparisons have been
made regarding the usage of protective equipment versus
the usage of skin care products [17]. Also, the efficiency
of skin care programmes including an educational elem-
ent has been examined. Both skin protection behaviour
and objectively assessed symptoms were beneficially
impacted in a group of health care personnel [18,19] and
among employees in the food care industry [20,21]. How-
ever in general, interventional prevention trials have had
methodological weaknesses and insufficient dimensions
in terms of power [16,18] and only few studies have
investigated skin protection programmes as a tertiary
preventive measure. In Germany, a combined health
educational and health psychological intervention i.e.
Tertiary Individual Prevention has been found to signifi-
cantly increase important factors related to skin protec-
tion behaviour [22]. This programme requires three
weeks of hospitalisation based upon employer-funded
health insurance. Hence, these results are not easily
transferred to a Danish health care system in which
chronic hand eczema is predominantly treated in an out-
patient setting. The current randomised controlled trial
evaluates the effectiveness of a newly developed nurse-
led counselling programme, based upon individual needs
and resources, compared to conventional patient infor-
mation given at medical consultations.Theoretical framework and regimen rationale
As aforementioned, chronic hand eczema is charac-
terised by eczematous eruptions occurring in active
phases of the disease. Medical treatment, primarily the
usage of topical corticosteroids, is required during these
eruptions. Periods between eruptions involve restitution
of the skin and prevention of future eruptions in the
context of daily life when the disease solely is handled
as the individual’s self-management. Throughout the
course, the individual may adapt to the condition in
several dimensions. The progress in disease severity
may lead to more apparent symptoms thus influencing
the individual’s self-monitoring of the condition. Also,
more severe eruptions of eczema may bring about
increased involvement from health care professionals.
Finally, the prolonged time frame and the repeated
relapses can promote changes in the individual’s ability
to cope and act upon disease-related problems based
on experiences and required knowledge. These patterns
of adaptation need to be considered in the support of
patients’ self-management.
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Objectives
The bulk of evidence mostly implies standardised inter-
vention within specific occupational sectors that in par-
ticular dispose to hand eczema through wet work.
However, in clinical dermatology practice the target group
is highly heterogenic involving individuals in different
phases of life and living under various conditions all of
which may influence their self-management. A need for
more individualised action plans and guidance yet still
feasible in an institutionalised context has been identified.
The aim of the trial ‘Chronic Hand Eczema - self-
management and prognosis’ is to evaluate if a newly
developed guidance programme bring about a better
prognosis of the disease at six months follow-up in com-
parison to conventional information.
Hypotheses
It is hypothesised that the intervention may support the
patients’ self-management to a degree that improvement
in objectively assessed severity of hand eczema is meas-
urable at a group level at six months follow-up com-
pared to that of a control group. Also, improvement in
subjectively assessed severity of disease and quality of
life is expected.
Empirical design
The hypotheses are tested through the conduct of a pro-
spective randomised controlled trial having a pragmatic
design [23]. The study is a multicenter trial as the setting
is an outpatient clinic in a university hospital within the
metropolitan area of the Danish capital, Copenhagen
(setting A), and a private dermatology practice in
Aalborg in northern Jutland, Denmark (setting B). For
the purpose of this paper both settings are referred to as
‘the dermatologist’.
Participants
Consecutive inclusion to the trial is performed. As soon
as an individual is referred to treatment at the derma-
tologist due to ‘hand eczema’, an information letter is
posted inviting the patient to participate in the trial. At
inclusion, i.e. at first medical consultation at the derma-
tologist, signed, written informed consent is obtained.
An objective evaluation of the present hand eczema is
performed prior to an individual randomisation to either
conventional information or to guidance according to
the intervention. To enhance external validity of the
trial, inclusion criterions are wide.
Inclusion criterions
▪ Patients aged between 18–70 years (hand eczema is
frequently work related and individuals older than70 years may in general have a different pattern of
exposure, which has to be considered at inclusion)
▪ A clinical diagnosis of hand eczema given by the
dermatologist at the first consultation
▪ Signed, written informed consent to participate
Exclusion criterions
▪ Patients in need of admittance to the dermatological
in-hospital ward at the time of inclusion or during the
follow up period
▪ Patients who cannot fill out a questionnaire in
Danish due to language difficulties or to a physical or
psychological handicap
Randomisation
Patients, who fulfil the inclusion criterions, are included
consecutively in the trial depending of time of their re-
ferral to the dermatologist. A baseline objective evalu-
ation of hand eczema severity is carried out prior to the
individual randomisation, which is performed centrally
at the National Allergy Research Centre using a
computer-generated algorithm unknown to the investi-
gator. The patients are allocated to the intervention
group, or conventional information in the control group.
The percentage of patients allocated to each group is ap-
proximately 50:50. Randomisation is stratified by blocks
according to setting and gender, the latter because of a
gender ratio of hand eczema, as women have the double
risk of men of hand eczema. Also, gender has been
shown to impact both performed self-management [24]
and ‘prescribed’ self-management [25].
The trial flow
When included in the trial, a baseline questionnaire is
handed to the participant. Evidence from randomised
trials suggests that in questionnaire design, ‘shorter is
better’ [26]. Thus, attempts have been made to make the
baseline questionnaire as short as possible. However,
given the conceptual broadness of ‘self-management’, the
questionnaire compiles items covering exposures, sus-
ceptibility, knowledge, medical adherence and self-
efficacy. Immediately after randomisation, an initial basic
counselling is given to participants in the intervention
group. An appointment of the subsequent nurse-led
consultation is offered to be conveniently executed in
timely relation to the next medical consultation. Also,
the patient is offered to choose between patient self-
management books of either physical or electronic form.
The trial flow is displayed in Figure 1.
Trial intervention
The trial aims at intervening multi modally through
initiatives which separately may be expected to support
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Figure 1 Trial flow chart.
Mollerup et al. BMC Dermatology 2012, 12:6 Page 4 of 9
http://www.biomedcentral.com/1471-5945/12/6patient self-management and to be beneficial to the
hand eczema prognosis [10,13,15,27-29]. The interven-
tion is named The Healthy Skin Clinic in order to em-
phasise that self-management of hand eczema is more
than medication adherence thus also involves health
promotion. The Healthy Skin Clinic complies with usual
clinical practice aiming to provide the patient with a sys-
tematic, yet individually, based counselling programme
including a support module. The Healthy Skin Clinic is
maintained by experienced nurses within the dermato-
logical specialty along with the investigator (setting A),
or by an experienced health care assistant supervised by
the investigator and a dermatologist (setting B). A high
level of team communication is conducted in order to
provide commonality of the intervention.
The intervention is founded upon three concur-
rent elements. Firstly, a SKIN-profile is generated byresponses from the baseline questionnaire. The profile is
descriptive of the patient regarding susceptibility; know-
ledge; co-morbidity; social support; and necessary pre-
cautions i.e. allergies and aggravating irritant factors.
One significant purpose of generating the profile is to
clarify the multifactorial aetiology of (the persistence of )
chronic hand eczema thus direct focus to the relevant
areas in the following nurse-led consultation.
Secondly, a patient self-management book is offered.
The book is a dynamic tool, which is launched in an
electronic form, i.e. a secure website. Patients, with
no possibilities of using information technology, will
be handed over a physical book containing the same
features. The patient self-management book contains
information material which is tailored to the SKIN-
profile. In addition, tools for self-monitoring of the
disease are offered with the purpose of encouraging
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course.
Finally, in addition to the nurse-led consultation, sup-
port to self-management through asynchronous commu-
nication and networking is offered. The online users
may facilitate contact to either the intervention team or
to other trial participants by use of the website. To the
users of the physical self-management book a telephone
based hotline is offered. An overall graphical depiction
of the Healthy Skin Clinic intervention is presented in
Figure 2 as this is a way proposed to clarify the content
of complex interventions [30].Conventional information
At present in Denmark, no standards or guidelines as to
information and guidance of patients with chronic hand
eczema exist. The patients in the control group will re-
ceive conventional information, i.e. written information
sheets, in relation to medical consultations and allergy
tests.Measurement
Due to difficulties of measuring health behaviour, inter-
ventional efficacy is to be assessed by the clinical impact
presumably brought about by the altered behaviour [27].
Hence, primary outcome variable is objectively assessed
disease severity.
At the inclusion point, a baseline investigation of both
control and intervention group is performed while col-
lecting data demographics, medical history and predis-
posing factors of eczema disease, as well as information
of occupational and leisure time related exposures.
Wherever possible, questionnaires used in the trial areFigure 2 Graphical depictions of interventions in the CHE-trial. Compo
activities (represented by circles) [30].based on previously validated scales (see below). The
variables will be re-evaluated at follow up after six
months.Primary outcome
Objective severity of hand eczema
The primary outcome variable is the change from base-
line (T0) to follow up in objectively assessed disease se-
verity, which is evaluated clinically by a member of the
intervention team. The assessment relies on the Hand
Eczema Severity Index (HECSI) which is a validated
scoring system developed to quantify severity of hand
eczema. HECSI is a visual medical assessment and sub-
jective symptoms of the patient, e.g. itch or pain are not
included [31]. Inter-rater variability in the present trial
will be evaluated by random checks where patients are
scored twice independently and by different assessors.Secondary outcome
Quality of life
The patient’s subjective symptoms will be measured by
Dermatology Life Quality Index (DLQI) and by parts of
Impact of Skin diseases on Daily Life (ISDL). DLQI is a
dermatology specific questionnaire of life quality which
has been used globally since 1994. At the moment DLQI
is the best validated instrument for measuring quality of
life among dermatological patients [32]. However, DLQI
is not reckoned to be adequate to evaluate the impact
that chronic hand eczema has on daily life and being of
the individual. ISDL is a newly developed multi dimen-
sional instrument which only exists in an English ver-
sion. So far, it has been validated to patients suffering
from psoriasis and atopic dermatitis [33]. It includesnents are regarded either as objects (represented by squares) or as
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quent phenomena also when it comes to hand eczema
and which is not noticeably covered by DLQI [33]. In
addition, a self constructed Visual Analogue Scale (VAS)
of perceived global burden of disease will be used.
Self-rated health status
As disease specific life quality presumably will be influ-
enced by co-morbidity and life quality in general, a
measurement of self-rated health will be conducted by
use of the frequently used generic Health Status Ques-
tionnaire, Short Form (SF-36).
Patient competencies
Several factors might affect the prognosis of chronic
hand eczema. These are included in the questionnaire i.
e. literacy; motivation for medication adherence and the
patient’s knowledge of causative exposure and manage-
ment of hand eczema [11,13-15,34].
Literacy is evaluated from questions of the highest
obtained education; Single-Item Literacy Screener; and
self-rated reading proficiency [35-37]. Moreover, subject-
ive action competence i.e. self-efficacy has been shown
to determine changes in health behaviour [38]. Self-
efficacy is measured at baseline through the Danish Ver-
sion of the General Self-Efficacy Scale. This is an instru-
ment which addresses self-efficacy as a concept related
to personality traits [39]. Medication adherence will be
evaluated by use of a Danish version of The Medication
Adherence Report Scale (DMARS-4). This is a generic
scale as yet solely validated to cancer patients in relation
to their analgesic treatment [40]. In addition the two
group’s primary medication adherence at follow up will
be evaluated by gathering of register data from the
Danish Medicines Agency [12]. Assessment of the
patients’ own knowledge of exposures and management
of their hand eczema will be carried out by use of parts
of Nordic Occupational Skin Questionnaire (NOSQ-
2002) [41]. This questionnaire is already available in a
Danish version. Finally, the investigator has added a sup-
plement of self-constructed questions regarding skin
protection behaviour at follow-up.
Sick leave
Information of self-reported sick leave related to hand
eczema both at baseline and at follow up will be
obtained through the questionnaire.
Possible confounders
Several factors might affect self-management capabilities
and the prognosis of disease thus are included in the
questionnaire i.e. socio-economic status; perceived social
support as well as depression and stress. In the data ana-
lysis a rough assessment of prevalent depression amongparticipants is done by items included in the mental
health sub-scale in SF-36 [42].
Statistical plan and data analysis sample size estimation
Studies examining patient compliance by the use of
intervention group and group of control patients are
usually recommended to include a minimum of 60 parti-
cipants in each group if an absolute difference in effect
of 25% between groups is to be demonstrated at a prob-
ability of 80% [14]. Medication adherence is not easily
measured in particular when it comes to dynamic condi-
tions like eczema with treatment being a combination of
a topical pharmaceutical and preventive behaviour [43].
Also, power calculation is hampered by uncertainty of
whether an individual action plan may promote a clinic-
ally improvement when under the influence of exogen-
ous factors related to the patient. In a previous study
that used HECSI-score as outcome variable an average
score of 11.2 was detected at six months follow-up com-
pared to an average score of 19.9 at baseline (n = 366)
[44]. With reference to this follow-up score in the con-
trol group and assuming an improvement of 30% due to
the intervention, a power calculation carry out a sample
size need of at least 87 patients in each group. In details,
the sample size is calculated based upon the following
values at six months follow-up along with estimated
standard deviations: Control group mean-HECSI 11 (SD
9.0) and Intervention group mean-HECSI 7.7 (SD 6.0).
Applying an alpha error level at 5%; and a beta error
level at 90%, the use of 2-samples average data input
bring forward a need of 87 participants in each
group to detect a difference (http:/www.ddsresearch.
com/toolkit/sscalc/size_a2.asp).
With a 15% excess of the number due to non-
parametric variables and with caution due to the hetero-
geneities of the sample, and to the probability of drop-
outs, it has been assessed that inclusion of 150 patients
in each group may be sufficient to show the anticipated
effect of the intervention in question. No studies with
estimated sample sizes based on ‘the minimal clinically
importan difference’ of life quality measures have been
identified. However, when using SF-36 as efficacy vari-
able a minimum of 71 patients in each group are
requested in order to demonstrate an achieved effect
size of 0.5 [45]. Others propose a minimum of 80 in
each group in interventional studies, targeting changes
in health behaviour [46]. Hence, both figures are within
the range of the present estimated sample size.
Statistical methods
All data obtained at baseline will be given a coded ID-
number before they are used in further statistical ana-
lyses. After double data entry and with the guidance of a
statistician, statistical analysis will be performed in SPSS.
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and descriptive statistics as well as multivariate analyses
will be conducted. Ordinal scaled data will be evaluated
as to a Gaussian distribution after which between-group
differences will be tested in accordance by the use of
t-test or non-parametric test. Dichotomous efficacy
variables are tested by use of chi2 test or exact test in
case of small numbers. The significance level will be a
p-value of less than 0.05.
The final number of patients included in the trial will
be reported and intention-to-treat analyses are to be per-
formed meaning all participants will be included in the
analysis irrespective of compliance with the intervention
protocol. However, an additional per-protocol analysis
will also be conducted. Data from patients who refused
to participate, dropouts, and loss-to-follow-up partici-
pants will be entered to an analysis based upon demo-
graphics in order to consider selection bias when
interpreting the results. The presentation of the trial
results will be according to the CONSORT statement to
Trials of Nonpharmacologic Treatment [47].
Ethical considerations
The trial protocol has been approved by the Danish Data
Protection Agency as well as the regional ethics commit-
tee (registration number H-2-2011-007). All data gath-
ered will be coded in order to secure anonymity of the
patient. Data are filed in secure drives and servers, and if
physical i.e. questionnaires data, stored in secured
archives thus only accessible to the investigator.
Risk/benefits
The intervention of the trial is non-pharmaceutical thus
potential risks relate to eventual wrongly given informa-
tion and advise about skin care and skin protection. It is
expected that misinformation will be hypothetical. The
patients in the intervention group are expected to gain
from the Healthy Skin Clinic in a way that makes them
more knowledgeable and confident of their eczematous
disease.
At present in Denmark, no standards or guidelines as
to information and guidance to patients with chronic
hand eczema exist. The patients in the control group
will receive conventional information, i.e. written infor-
mation sheets, in relation to medical consultations and
allergy tests. Hence, they are not deprived from any
usual care. By the end of the trial, participants in the
control group are offered counselling given analogous to
the Healthy Skin Clinic.
Informed consent
By giving the signed, informed consent, participants
accept to be informed of 1) the aim of the trial, 2) the
voluntariness of their participation, 3) the fact that noconsequences to the individual will occur as to continu-
ous treatment if they choose to withdraw their consent,
and 4) that all data concerning their health and daily life
is to be used only with anonymity.
Trial conduct
The trial will be conducted in compliance with the
protocol, and no deviations from the protocol will be
implemented without the prior review and approval of
the regulatory authorities i.e. the Danish Data Protection
Agency and the regional ethics committee.
Blinding
The trial complies with usual clinical practice and the
involved health professional actors will be the investiga-
tor and the members of the intervention team. It has
been judged not to be feasible to maintain a fully blinded
design throughout the trial. An effort is made to prevent
performance bias by making the HECSI-scoring prior to
randomisation. The HECSI scores are then removed
from the participants’ data file to make the outcome as-
sessment as blinded as possible. Also, when measuring
primary outcome at six months follow-up, attempts are
made to randomly allocate the member of the team,
who does the HECSI-scoring. Hence, the participant
may have been included by one member of the team;
have been counselled by another; and have had final out-
come assessed by a third member of the intervention
team.
Trial duration and discontinuation of individual
participants
Duration of patients’ participation will be until follow-up
six months after inclusion. It may be that the patient is
discharged from treatment prior to date of completion
or that dermatological treatment is necessary for a
longer period than six months. However, outcome vari-
ables will be evaluated at six months follow up and no
further intervention will be offered. The participants
may continue to use the newly developed website, which
is hosted and maintained by the National Allergy Re-
search Centre. This includes access to information; the
self-monitoring tool i.e. a personal log as well as the pa-
tient dialogue forum.
Discussion
In this paper the protocol of a large randomised con-
trolled trial in the clinical field of Dermatology is pre-
sented. The trial aims at evaluating a newly developed
guidance programme which is expected to support self-
management of patients referred to dermatology treat-
ment due to chronic hand eczema. The design of the
protocol is pragmatic and data analysis will be con-
ducted with blinding of neither participants nor the
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in the interpretation of the results. However, allocation
to the two arms in the trial i.e. the intervention group
and the control group is done by randomisation per-
formed after the baseline assessment of the primary out-
come variable. Other efforts are done in order to
increase rigor of the trial. In the follow-up assessment of
outcome variables, attempts are made ‘to be oblivious
of ’ the severity scores at baseline by deliberate removal
of these sheets from the data files. Furthermore, the ran-
domness inherent in the process of being a team of
assessors both at baseline and at follow-up may prevent
observer bias.
Finally, in the interpretation of the results, the investi-
gator takes into account effects that may be attributed to
actors of the interventions rather than the intervention
per se [47,48].
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